Several studies have shown that CD4+ TILs are associated with improved outcomes in ovarian cancer, likely due to their role in recruiting and activating CD8+ T cells, although others have reported no association or even a negative impact on prognosis [25,45,46,47]. This evidence concerns the gene CD8A and ovarian carcinoma.